Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: Results of a feasibility exercise

Vox Sanguinis

Volumn 109, Issue 4, 2015, Pages 387-393

  Bunos, M ^a   Hummer C ^a   Wingenfeld, E ^a   Sorg, N ^a   Pfirrmann, V ^b   Bader, P ^b   Seifried, E ^a,b   Bönig, Halvard ^a,b,c  

^a Institute Frankfurt   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adoptive transfer; Automation; CCS; CliniMACS; CMV; GMP

Indexed keywords

GAMMA INTERFERON; REAGENT; CYTOKINE;

ANTIGEN SPECIFICITY; ARTICLE; CD3+ T LYMPHOCYTE; CELL ISOLATION; CELL SORTER; CELL STIMULATION; CLINIMACS PLUS SYSTEM; CLINIMACS PRODIGY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DONOR; FEASIBILITY STUDY; HUMAN; HUMAN CELL; LABORATORY AUTOMATION; LABORATORY DEVICE; LEUKAPHERESIS; NORMAL HUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; DEVICES; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES;

CYTOKINES; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 84944279474     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12291     Document Type: Article

References (20)

1. Gerdemann U, Katari UL, Papadopoulou A, et al.: Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013; 21:2113-2121
2. Saglio F, Hanley PJ, Bollard CM: The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 2014; 16:149-159
3. Sellar RS, Peggs KS: The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy 2012; 14:391-400
4. Feuchtinger T, Lang P, Hamprecht K, et al.: Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32:282-289
5. Kapp M, Tan SM, Einsele H, et al.: Adoptive immunotherapy of HCMV infection. Cytotherapy 2007; 9:699-711
6. Thomas S, Herr W: Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation. Immunotherapy 2011; 3:771-788
7. Peggs KS, Thomson K, Samuel E, et al.: Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52:49-57
8. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044
9. Feuchtinger T, Opherk K, Bethge WA, et al.: Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116:4360-4367
10. Qasim W, Derniame S, Gilmour K, et al.: Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol 2011; 154:150-153
11. Amir AL, D'Orsogna LJ, Roelen DL, et al.: Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115:3146-3157
12. Schmitt A, Tonn T, Busch DH, et al.: Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51:591-599
13. Wang XC, Pang H, Xu X, et al.: Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. J Formos Med Assoc 2013; 112:338-345
14. Feuchtinger T, Matthes-Martin S, Richard C, et al.: Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134:64-76
15. Icheva V, Kayser S, Wolff D, et al.: Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31:39-48
16. Mackinnon S, Thomson K, Verfuerth S, et al.: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008; 40:63-67
17. Apel M, Bruning M, Granzin M, et al.: Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chem Ing Tech 2014; 85:103-110
18. Sorg N, Poppe C, Bunos M, et al.: Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. Transfusion. e-published 2015. doi: 10.1111/trf.13001. [Epub ahead of print]
19. Richter A, Preussner L, Traska V, et al.: Virus-specific T lymphocytes maintain their in vivo phenotype and functional competence after automated processing to generate a cellular product for immunotherapy. Blood 2013; 122:3268
20. Schulz M, Bialleck H, Thorausch K, et al.: Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. Transfusion e-published 2014; 54:1622-1629